# Symbiox Investment & Trading Co. Ltd.

221, Rabindra Sarani, 3rd Floor Room No. - 1, Kolkata - 700 007 Contact : 98302 74227 CIN : L65993WB1979PLC032012 Website : www.symbioxinvestment.com E-mail : symbioxinvestment100@gmail.com

### Date: 13th February, 2024

To,	To,	To,
<b>Compliance Department</b>	The Calcutta Stock	The Bombay Stock
Metropolitan Stock Exchange of India	<b>Exchange</b> Limited	Exchange Limited,
Vibgyor Towers, 4th floor, Plot No C 62,		PJ Towers, Dalal Street
Block, Opp. Trident Hotel, Bandra	Kolkata- 700 001	Mumbai- 400 001
Kurla Complex, Bandra (E),		
Mumbai – 400 098		

## Subject: Outcome of Board Meeting of the Company for the quarter ended 31<sup>st</sup> December, 2023 held on 13<sup>th</sup> February, 2024- Results

<u>Ref.: Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure</u> <u>Requirements) Regulations, 2015</u>

BSE Scrip Code: 539278 CSE Scrip Code: 029461 Symbol: SYMBIOX

Dear Sir,

Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Regulations"), the Board of Directors of the Company at its Meeting held today i.e., **13**<sup>th</sup> February, 2024, have inter-alia considered and approved-

1. Un-audited Financial Results for the quarter ended December 31, 2023;

Accordingly, with regards to aforesaid, we. are enclosing herewith the following:

a. Un-audited Financial Results for the quarter ended December 31, 2023;

b. Auditors Limited Review Report on the Results for the quarter ended December 31, 2023.

The meeting of Board of Directors commenced at 1:30 P.M. and concluded at 2:50 P.M.

Please take the same on your record and acknowledge the receipt of the same.

Thanking You. Yours Faithfully,

## For Symbiox Investment & Trading Co Ltd

Kifut

Khusboo Pitti Company Secretary M. No. 25950



# SYMBIOX INVESTMENT & TRADING CO LTD

# 221, RABINDRA SARANI, 3RD FLOOR, ROOM NO-1, KOLKATA -700007

CIN - L65993WB1979PLC032012

#### Email - symbioxinvestment100@gmail.com; Website: www. symbioxinvestment.com

Satement of Unaudited Financial Result for the Quarter and nine month ended 31st Dec, 2023

	Particulars	Quarter ended			Nine month		kh except EPS) Year ended	
		31.12.2023 Unaudited	2.2023 30.09.2023	31.12.2022	31.12.2023	31.12.2022 31-	31-03-2023	
				Unaudited	Unaudited		Audited	
1	Revenue From Operations	18.26	123.22	37.50	277.63	360.75	398.24	
Ш	Other Income	5.81	3.00	11.46	20.32	52.17	1.64	
Ш	Total Income (I+II)	24.07	126.22	48.96	297.95	412.92	399.88	
IV	EXPENSES	Jedie Sarah						
	Cost of materials consumed	- 12	-	-	0.00	0.00	0.00	
	Purchases of Stock-in-Trade	22.49	30.83	42.50	232.62	297.50	343.97	
	Changes in inventories of finished goods,							
	Stock-in -Trade and work-in-progress	-3.29	68.67	0.00	3.04	0.00	-20.80	
	Employee benefits expense	4.25	5.50	0.75	14.54	10.87	19.22	
	Finance costs	0.00	0.00	0.00	0.00	0.00	0.00	
	Depreciation and amortization expense	0.05	0.05	0.00	0.10	0.00	0.00	
	Other expenses	1.78	3.46	2.78	15.80	13.41	35.94	
	Total expenses (IV)	25.28	108.51	46.03	266.10	321.78	378.33	
V	Profit/(loss) before exceptional items and tax (I- IV)	-1.21	17.71	2.93	31.85	91.14	21.55	
VI	Exceptional Items	-	-	-			0.00	
	Profit/(loss) before tax							
VII	(V-VI)	-1.21	17.71	2.93	31.85	91.14	21.55	
VIII	Tax expense:							
	(1) Current tax	0.31	4.59	2.68	8.28	23.70	5.64	
	(2) Deferred tax	-	-	-		0.00	0.00	
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	-0.90	13.12	0.25	23.57	67.44	15.91	
Х	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	-0.90	13.12	0.25	23.57	67.44	15.91	
XIII	Profit/(loss) for the period (IX+XII)	-0.90	13.12	0.25	23.57	67.44	15.91	
XIV	Other Comprehensive Income							
	A (i) Items that will not be reclassified to profit or loss	-	-	-				
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	_	-	-	_		



	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-		
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-		
XV	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-	-	-	-	-		
	Paid up equity share Capital ( No. of Shares)	31287330	31287330	31287330	31287330	31287330	31287330	
_	Face Value	10.00	10.00	10.00	10.00	10.00	10.00	
XVI	Earnings per equity share (for continuing operation):							
	(1) Basic	-0.003	0.0419	0.001	0.075	0.216	0.051	
	(2) Diluted	-0.003	0.0419	0.001	0.075	0.216	0.051	
XVII	Earnings per equity share (for discontinued operation):							
	(1) Basic	0.000	0.000	0.000	0.000	0.000	0.000	
	(2) Diluted	0.000	0.000	0.000	0.000	0.000	0.000	
XVIII	Earnings per equity share(for discontinued & continuing operations)							
	(1) Basic	0.000	0.000	0.000	0.000	0.000	0.000	
	(2) Diluted	0.000	0.000	0.000	0.000	0.000	0.000	
Note:								
1	The above Unaudited financial results were reviewed by Audit Committee and approved by the Board of Directors in their meeting held on 13th February, 2024							
2	The previous period figures have been regrouped wherever necessary.							
3	The Statutory auditors of the Company have carried out a "Auditor's report" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.							

The Company has adopted Indian Accounting standards (Ind AS) with effect from 01<sup>st</sup> April, 2017 and accordingly, the above results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013

5 The above results for the quarter & nine month ended 31st Dec.,2023 along with Auditor Report has been approved by the Board of Directors of the Company.

6 There are no qualification in the Audit Report issued by the Auditor

For and behalf of Board SYMBIOX INVESTMENT & TRADING CO LTD

Place: Kolkata Date: 13.02.2024 Simit

Samit Ray Managing Director DIN No.08406285



#### SSRV & Associates Chartered Accountants

Head Office :- Office No.215, 2nd Floor, Gundecha Ind. Estate, Akurli Road, Kandivali (E), Mumbai - 400 101. Tel:+91 22-67337024 / +91 22-67337025 | Email: ssrvandassociates@gmail.com

Independent Auditor, Review Report on Quarterly Unaudited Standalone Financial Result of Symbiox Investment & Trading Co. Limited pursuant to the Regulation 33 and Regulation 52 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended.

To

The Board of Directors, Symbiox Investment & Trading Co. Limited 221, Rabindra Sarani, 3rd Floor, Room No. 1, Kolkata-700007.

- 1. We have reviewed the accompanying statements of unaudited Standalone Financial Results of Symbiox Investment & Trading Co. Limited ('the Company") for the quarter ended December 31, 2023 and year to date from April 01. 2023 to December 31, 2023 (the "Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed, under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulations 33 and 52 of the Listing Regulations. The Statement has been approved by the Company's Board of Director's. Our responsibility is to express a conclusion on the statement based on our review.
- We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

(Chartered Accountants) Firm Reg. No.: 135901W 8 SSOG ISHNUXCH Vishnu Kant Kabra TAL.A (Partner) WENS NO. M. No.: 403437 403437 Place: Mumbai Date: 13th February, 2024 RIER UDIN: 24403437BKAITT4757

For S S R V & Associates